TW202227060A - 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 - Google Patents

利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 Download PDF

Info

Publication number
TW202227060A
TW202227060A TW110134368A TW110134368A TW202227060A TW 202227060 A TW202227060 A TW 202227060A TW 110134368 A TW110134368 A TW 110134368A TW 110134368 A TW110134368 A TW 110134368A TW 202227060 A TW202227060 A TW 202227060A
Authority
TW
Taiwan
Prior art keywords
dosing
day
group
days
week
Prior art date
Application number
TW110134368A
Other languages
English (en)
Chinese (zh)
Inventor
上野裕之
星野卓哉
Original Assignee
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202227060A publication Critical patent/TW202227060A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110134368A 2020-09-15 2021-09-15 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 TW202227060A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078844P 2020-09-15 2020-09-15
US63/078,844 2020-09-15

Publications (1)

Publication Number Publication Date
TW202227060A true TW202227060A (zh) 2022-07-16

Family

ID=80776678

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110134368A TW202227060A (zh) 2020-09-15 2021-09-15 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法

Country Status (7)

Country Link
US (1) US20230390251A1 (https=)
EP (1) EP4213842B1 (https=)
JP (1) JP7828333B2 (https=)
KR (1) KR20230067647A (https=)
AU (1) AU2021345171A1 (https=)
TW (1) TW202227060A (https=)
WO (1) WO2022059692A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
US10889555B2 (en) * 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US20200405697A1 (en) * 2017-11-29 2020-12-31 Taiho Pharmaceutical Co., Ltd. Antitumor Agent

Also Published As

Publication number Publication date
EP4213842A4 (en) 2024-07-17
JP2023541432A (ja) 2023-10-02
AU2021345171A9 (en) 2024-02-08
AU2021345171A1 (en) 2023-05-25
US20230390251A1 (en) 2023-12-07
EP4213842A1 (en) 2023-07-26
JP7828333B2 (ja) 2026-03-11
WO2022059692A1 (en) 2022-03-24
KR20230067647A (ko) 2023-05-16
EP4213842B1 (en) 2026-04-15

Similar Documents

Publication Publication Date Title
JP7828333B2 (ja) リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法
CN113038953B (zh) 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法
WO2022059691A1 (en) Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor
CN121487738A (zh) 诱导ras gtp水解的组合物和其用途
KR20240168510A (ko) Kras g12d 및 g12v 돌연변이 표적 화합물 및 그 용도
AU2022355189B2 (en) Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
WO2025006697A1 (en) Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr
RU2848459C1 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
TWI914404B (zh) 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法
RU2859365C2 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
US20240408100A1 (en) Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway
WO2026015825A1 (en) Use of ras inhibitor for treating pancreatic cancer
HK40129790A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2025255438A1 (en) Methods of treating a ras protein-related disease or disorder
HK40051935A (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40051935B (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40055650A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers